CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP), is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development in Europe.

10 feb 2021 Cantargia utvecklar antikroppsbaserade läkemedel mot interleukin-1 receptor accessory protein (IL1RAP). Antikroppen CAN04 binder IL1RAP

no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04, is being studied 2019-6-2 · CAN04 is a humanized and antibody-dependent cellular cytotoxicity (ADCC)-enhanced IgG1 antibody targeting IL1RAP with two modes of action: blocking IL-1 alpha and beta signaling and triggering ADCC. This study included 22 patients with non–small cell lung cancer (NSCLC; four patients), pancreatic ductal adenocarcinoma (six patients), or The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform. The main project, the antibody CAN04 (nidanilimab) is being studied in the clinical phase I/IIa CANFOUR with a primary focus on non-small cell lung cancer and pancreatic cancer.

Cantargia can04

We have made progress both on our main project, CAN04, and on our second project, CAN10.” STOCKHOLM, Oct. 2, 2020 /PRNewswire/ -- Cantargia AB today announced that the first patient has started treatment with the antibody CAN04 and pembrolizumab in a phase I clinical trial in USA. The trial continues according to the clinical protocol and will include up to 18 patients. 2021-03-10 · Forskningsbolaget Cantargia ansöker om att få starta en tredje parallell studie med antikroppen CAN04, denna gång i kombination med cellgiftet folfirinox mot bukspottkörtelcancer. Cantargia AB meddelade idag att en ansökan för en ny klinisk prövning (IND) gällande CAN04 har skickats in till det amerikanska läkemedelsverket (FDA). CAN04 är en antikropp som är riktad mot interleukin 1 receptor accessory protein (IL1RAP). CAN04 undersöks för behandling av icke-småcellig lungcancer (NSCLC) och Cantargia AB meddelade idag uppdaterade interimsresultat från den pågående kliniska studien med antikroppen CAN04, som blockerar interleukin-1 receptor accessory protein (IL1RAP), i kombination med cellgifter vid behandling av icke-småcellig lungcancer (NSCLC).

Cantargia AB today announced the submission of a clinical trial application investigating antibody CAN04 in combination with FOLFIRINOX for first line treatment of metastatic pancreatic cancer (PDAC).

2021-2-26 · Cantargia AB today announced that the IND application regarding the antibody CAN04 has been approved by the US FDA. CAN04, an antibody targeting interleukin 1 receptor accessory protein (IL1RAP), is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development.

”Cantargia har lyckats att utföra de flesta kritiska processerna under denna första fas av COVID-19-utbrottet med en minimal påverkan på tidslinjer för utvecklingen. Viktigast av allt är att den initiala doseskaleringsfasen i CANFOUR-studien har avslutats och en dosnivå på 5 mg/kg har valts för kombinationsterapin med CAN04. STOCKHOLM (Nyhetsbyrån Direkt) Forskningsbolaget Cantargias läkemedelskandidat Can04 har ett bredare angreppssätt än Novartis canakinumab (ACZ885) som i studien Canopy-2 inte uppnådde sitt primära mål i fas 3 enligt besked från det schweiziska bolaget på tisdagen. Det uppger vd Göran Forsberg uppger för Nyhetsbyrån Direkt.

Cantargia utvecklar antikroppsbaserade läkemedel mot interleukin-1 receptor accessory protein (IL1RAP). Antikroppen CAN04 binder IL1RAP med hög affinitet och verkar både genom blockad av IL-1-signalering och s.k. Antibody-Dependent Cellular Cytotoxicity (ADCC). Prekliniska data visar att CAN04 kan öka effekten av cellgifter.

Cantargia avancerar utvecklingen av CAN04 genom framgångsrik uppskalning av produktionen fre, feb 14, 2020 12:30 CET. Cantargia AB (publ) tillkännagav idag att bolaget har nått en viktig milstolpe under utvecklingen av sitt antikroppsprojekt CAN04, som är i kliniska fas IIa-studier för cancerbehandling, med den första GMP-produktionen av CAN04 i en volym på 2 000 liter. Cantargia reports high response rates with CAN04 combination therapy in NSCLC and presents next development steps PRESS RELEASE PR Newswire Sep. 23, 2020, 12:39 PM Cantargia reports high response rates with CAN04 combination therapy in NSCLC and presents next development steps Wed, Sep 23, 2020 12:15 CET. Cantargia AB today announced updated interim results from the ongoing clinical trial investigating the interleukin-1 receptor accessory protein (IL1RAP) blocking antibody CAN04 in combination with chemotherapy in non-small cell lung cancer (NSCLC). 2021-03-10 (R) Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och FOLFIRINOX i bukspottkörtelcancer 2021-03-01 Cantargia ger verksamhetsuppdatering vid investerarkonferenser under mars 2021 Cantargia ansöker om start av ny klinisk studie kring antikroppen CAN04 och FOLFIRINOX i bukspottkörtelcancer ons, mar 10, 2021 08:30 CET. Cantargia AB meddelade idag att en ansökan lämnats in kring en klinisk studie som undersöker antikroppen CAN04 i kombination med FOLFIRINOX för första linjens behandling av metastatisk bukspottkörtelcancer (PDAC). ”Looking back at the past year, Cantargia now stands on even firmer ground than we did a year ago, despite everything.

Analyser, rekommendationer & riktkurser för Cantargia aktien. Cantargia: Stärkta i vår uppfattning om CAN04. Interimsdata som Vi adderar 7,3 kronor/aktie för den stora potentialen för CAN04 i kombination med Keytruda och summerar värdet av Cantargias olika projekt… Vi adderar 7,3 Cantargia has formally applied to start a phase I/IIa clinical trial with its proprietary antibody CAN04, directed towards the molecular target IL1RAP This is "Fördelar med CAN04" by Cantargia on Vimeo, the home for high quality videos and the people who Cantargia develops antibody-based pharmaceuticals against interleukin-1 receptor accessory protein (IL1RAP). The antibody CAN04 binds IL1RAP with high affinity and functions through both Antibody-Dependent Cellular Cytotoxicity (ADCC) and blockade of interleukin-1 (IL-1) signaling. Cantargia develops antibody-based pharmaceuticals against IL1RAP.
Körkort fyrhjuling

By acquiring this IP, we have secured all relevant IP on IL1RAP as a target for cancer therapy", said Göran Forsberg, CEO of Cantargia.

2021-03- Latest Cantargia AB (CANTA:STO) share price with interactive charts, start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can An anti-IL1RAP monoclonal antibody (CAN04, nidanilimab) has been designed by Cantargia as a novel immunomodulator and it is being evaluated for potential 20 Oct 2018 2018 in Munich, Germany, shows that 6 mg/kg of nidanilimab (CAN04; Cantargia AB) was well tolerated and can be considered a safe dose.
Anders moberg ikea

Cantargia is now in the process of broadening the development activities and the next step is a phase Ib trial investigating CAN04 in combination with the PD1 binding antibody pembrolizumab

Antibody-Dependent Cellular Cytotoxicity (ADCC). Prekliniska data visar att CAN04 kan öka effekten av cellgifter. CAN04 i nivå med de resultat som den nya immunomodulerande antikroppen Keytruda (pembrolizumab, Merck) nyligen visat i en fas 2-studie (KEYNOTE-799) på 216 svårt sjuka NSCLC-patienter (icke operabelt stadium III).